JC03 Rec'd PCT/PTO 2 3 SEP 2004 P28506.P01 U.S. DEPARTMENT OF COMMERCE ATTORNEY'S DOCKET NUMBER Form PTO-1390 PATENT AND TRADEMARK OFFICE P28506 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APRLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/EP2003/013008 20 November 2003 24 March 2003 TITLE OF INVENTION USE OF 5-SUBSTITUTED NUCLEOSIDES FOR REINFORCING THE APOPTOTIC EFFECT OF CYTOSTATIC DRUGS APPLICANT(S) FOR DO/EO/US Rudolf FAHRIG, Joerg-Christian HEINRICH, and Georg KRUPITZA Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3.

This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below. The US has been elected (PCT Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. X is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). a. is attached hereto. b. Thas been previously submitted under 35 U.S.C. 154 (d) (4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a.

are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau.
c. have not been made; however, the time limit for making such amendments has NOT expired. d. \square have not been made and will not be made. 8.
An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. .371(c)(4)). "Unexecuted" 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 22 below concern other document(s) or information included: 11. Assignee: RESprotect GmbH, of Dresden, German 12.
An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 15. An Application Data Sheet under 37 C.F.R. 1.76. 16. A substitute specification. 17. A power of attorney and/or change of address letter. 18. A Figure of Drawing to be published: 1 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 20. A second copy of the published international application under 35 U.S.C. 154 (d) (4). 21. A second copy of the English language translation of the international of the international application under 35 U.S.C. 154 (d) (4). 22. Other items or information: Cover Letter under 35 U.S.C. 371 and 37 C.F.R. 1.495. Preliminary Amendment and Cover Letter Submitting Amended Pages of Application. English translation of Annex Amended Pages 1-2. International Application as published in German. PCT/ISA/210 International Search Report (in English and German). PCT/ISA/220 (in German). PCT/RO/101 PCT Request (in German). PCT/IPEA/409 International Preliminary Examination Report and Annex (in German). PCT/IPEA/416 (in German). PCT/IB/301. PCT/IB/304.

Claim of Priority.

REGISTRATION NUMBER



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rudolf FAHRIG et al.

Mail Stop PCT

Appl. No.:

Not Yet Assigned (National Phase of PCT/EP2003/013008)

I.A. Filed:

November 20, 2003

For

USE OF 5-SUBSTITUTED NUCLEOSIDES FOR REINFORCING THE

APOPTOTIC EFFECT OF CYTOSTATIC DRUGS

COVER LETTER ACCOMPANYING U.S. NATIONAL STAGE PATENT APPLICATION FILED UNDER 35 U.S.C. 371 AND 37 C.F.R. 1.495

Mail Stop PCT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop PCT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Enclosed is a new National Stage patent application for filing in the U.S. Patent and Trademark Office under 35 U.S.C. 371 and 37 C.F.R. 1.495. The Declaration and Power of Attorney attached thereto are in unexecuted form. A properly executed Declaration and Power of Attorney of the International Application as filed, will be filed within the period of time set in a Notification to be mailed by the United States Patent and Trademark Office.

Related to the above, this application should be associated with Customer Number 07055, which includes the present correspondence address as follows:

GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 P28506.P02

JC20 Rec'd PCT/PTO 2 3 SEP 2005

If there are any questions pertaining to this National Stage Application, please contact the undersigned.

Respectfully submitted, Rudolf FAMBIG et al.

Neil F. Greenblum Reg. No. 28,394

September 23, 2005 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191